TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teclison Ltd.
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations

• mCRC progressed on at least two lines of standard chemotherapy; or

• NSCLC progressed on chemotherapy and an immune checkpoint inhibitor

• Measurable disease

• ECOG 0-1

• Adequate organ function

Exclusion Criteria:

• Prior organ transplantation

• Liver metastasis more than 50%

• Oxygen saturation less than 92% in room air

• Prior autoimmune disorder

• CNS metastasis

• Major GI bleeding in the last 2 months